The complaint says that EOFlow developed its EOPatch insulin delivery system with the help of former Insulet employees and Insulet’s contract manufacturer. Medtronic announced plans to acquire EOFlow in May, and US FDA clearance is on the horizon.

In this third Exec Chat with leaders at major diabetes companies that presented at ADA’s Scientific Sessions 2023, Medtech Insight interviewed Medtronic diabetes business leaders Ali Dianaty and Jennifer McVean about the company’s marketing strategy for the recently launched MiniMed 780G with meal detection technology, plans for the Simplera disposable CGM, outlook on the consumer market, and more.  

This week, Medtronic said it would pay $738m for insulin patch firm EOFlow; Neuralink got an FDA OK for first-in-human trials; and UK agency NICE backed genetic tests for stroke patients and digital therapeutics for mental health conditions.

Plus deals involving GC Cell/Rivaara Immune, Sperogenix/Santhera, EOFlow/Zihipp, Grand/ITM, Tasly/Sutro, LegoChem/Iksuda, Nuance/Aerogen, Frontier/AffiRiS and Piramal/Yapan.